Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy.

Toll-like receptors (TLR)s are homo- or heterodimeric proteins, whose structure and function were widely described in the antigen presenting cells (APC), such as Dendritic cells (DC). Recently, the expression and the role of TLRs in fighting against pathogens, was described also in NK cells. Their activation and functional properties can be directly and indirectly modulated by agonists for TLRs. In particular CD56bright NK cells subset, that is the most abundant NK cell subset in tissues and tumor microenvironment (TME), was mostly activated in terms of pro-inflammatory cytokine production, proliferation and cytotoxicity, by agonists specific for endosomal TLR8. The interplay between DC and NK, that depends on both cell-to-cell contact and soluble factors such as cytokines, promote both DC maturation and NK cell activation. Based on this concept, a TLR based immunotherapy aimed to activate NK-DC axis, may modulate TME by inducing a pro-inflammatory phenotype, thus improving DC ability to present tumor-associated antigens to T cells, and NK cell cytotoxicity against tumor cells. In this mini-review, we report data of recent literature about TLRs on human NK cells and their application as adjuvant in cancer vaccines or in combined tumor immunotherapy. Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Citation

Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi. Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy. Immunology letters. 2023 Sep;261:13-16

Mesh Tags

Substances

PMID: 37451320

search → result